CREATE Medicines Raises $122 Million for CAR-T Therapy Development

CREATE Medicines raised $122 million in a funding round led by Newpath Partners, ARCH Venture Partners, and Hatteras Venture Partners to advance its CAR-T therapy candidates through human trials. The company, previously known as Myeloid Therapeutics until its fall 2025 rebrand, develops CAR-T therapies using myeloid cells designed to attack solid tumors and expanded into autoimmune disease research. Siddhartha Mukherjee, a writer and oncologist, cofounded the company.

CREATE Medicines funding round

• ▪CREATE Medicines' $122 million funding will propel CREATE Medicines' first CAR-T candidates through human trials
• ▪CREATE Medicines raised $122 million in a funding round
• ▪ARCH Venture Partners participated in CREATE Medicines' $122 million funding round

Company rebrand from Myeloid

• ▪CREATE Medicines was previously known as Myeloid Therapeutics until 2025
• ▪CREATE Medicines expanded into autoimmune disease research in fall 2025
• ▪CREATE Medicines' myeloid cell CAR-T therapies are designed to attack solid tumors
• ▪Myeloid Therapeutics rebranded to CREATE Medicines in fall 2025
• ▪CREATE Medicines develops CAR-T therapies using myeloid cells as immune agents

Siddhartha Mukherjee cofounder role

• ▪Siddhartha Mukherjee is a writer and oncologist
• ▪Siddhartha Mukherjee cofounded Myeloid Therapeutics